

**In the Claims**

Claims 1 – 12 (Cancelled)

13. (Currently Amended) A method of ~~inhibiting angiogenesis, tumor invasion, or formation of~~ decreasing intratumoral vessels to inhibit growth of melanoma and pulmonary metastases in a mammal comprising:

administering to the mammal a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID NO. 1.

14. (Previously Presented) The method according to claim 13, wherein the nucleic acid molecule is inserted into an expression vector.

15. (Previously Presented) The method according to claim 14, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.

16. (Currently Amended) The method according to claim 15, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1metargin.

17. (Currently Amended) A method of treating cancermelanoma in a mammal comprising decreasing intratumoral vessels to inhibit growth of the melanoma by administering a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID No. 1.

18. (Previously Presented) The method according to claim 17, wherein the nucleic acid molecule is inserted into an expression vector.

19. (Previously Presented) The method according to claim 18, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.

20. (Currently Amended) A method according to claim 19, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1metargin.

21. (Currently Amended) A method of treating psoriasis pulmonary metastases in a mammal comprising inhibiting the metatases by decreasing intratumoral vessels by administering a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID NO. 1.

22. (Previously Presented) The method according to claim 21, wherein the nucleic acid molecule is inserted into an expression vector.

23. (Currently Amended) The method according to claim [[22]]24, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1metargin.

24. (New) The method according to claim 22, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.